MarketCap
Facebook
X
TelegramAnnual report 2022
added 03-29-2023
Chembio Diagnostics Operating Income 2011-2026 | CEMI
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Chembio Diagnostics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -23.6 M | -31.1 M | -23.1 M | -13.3 M | -7.98 M | -6.48 M | -7.57 M | -3.55 M | -1.55 M | 1 M | 1.45 M | 1.09 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.45 M | -31.1 M | -9.56 M |
Quarterly Operating Income Chembio Diagnostics
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | -5.99 M | - | -8.05 M | - | -5.63 M | -8.34 M | -3.86 M | - | -4.91 M | -7.27 M | -4.42 M | - | -3.61 M | -3.3 M | -3.1 M | - | -2.33 M | -1.75 M | -654 K | - | -589 K | -2.18 M | -1.63 M | - | -2.14 M | -2.39 M | -468 K | - | -579 K | -898 K | -875 K | - | -262 K | -233 K | -383 K | - | 1.07 M | -380 K | 487 K | - | -485 K | 512 K | 720 K | - | 479 K | 197 K | -139 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.07 M | -8.34 M | -2.1 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Medpace Holdings
MEDP
|
535 M | $ 460.74 | 0.83 % | $ 13.3 B |  USA |
 |
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Bioventus
BVS
|
54 M | $ 9.15 | 1.67 % | $ 610 M | USA |
|
Biodesix
BDSX
|
-34.5 M | $ 15.54 | 5.79 % | $ 2.02 B | USA |
 |
Myriad Genetics
MYGN
|
-387 M | $ 4.61 | -1.07 % | $ 427 M | USA |
|
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
National Research Corporation
NRC
|
22.6 M | $ 17.44 | -0.4 % | $ 390 M | USA |
 |
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
Check-Cap Ltd.
CHEK
|
-25.9 M | - | - | $ 9.42 M |  Israel |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
Aspira Women's Health
AWH
|
-32.8 M | - | -6.19 % | $ 10.5 M | USA |
 |
Co-Diagnostics
CODX
|
-42.7 M | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Pacific Biosciences of California
PACB
|
-554 M | $ 1.39 | - | $ 417 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-14 M | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M |  China |
 |
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | China |
 |
Charles River Laboratories International
CRL
|
25.2 M | $ 159.19 | 0.75 % | $ 7.89 B | USA |
 |
IQVIA Holdings
IQV
|
2.18 B | $ 166.09 | -0.52 % | $ 28.6 B | USA |
 |
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | USA |
 |
Personalis
PSNL
|
-68.3 M | $ 7.78 | 2.23 % | $ 461 M | USA |
 |
Invitae Corporation
NVTA
|
-94.9 M | - | - | $ 21.2 M | USA |
 |
BioNano Genomics
BNGO
|
-33.3 M | $ 1.18 | -19.18 % | $ 6.43 M | USA |
 |
Interpace Biosciences
IDXG
|
8.11 M | $ 1.71 | 0.73 % | $ 7.5 M | USA |
 |
Illumina
ILMN
|
-833 M | $ 125.98 | 1.77 % | $ 20 B | USA |
 |
RadNet
RDNT
|
62 M | $ 59.87 | -3.03 % | $ 4.5 B | USA |
 |
QIAGEN N.V.
QGEN
|
97.7 M | - | - | $ 10.6 B |  Niderland |
 |
Precipio
PRPO
|
-7.62 M | $ 26.6 | -1.23 % | $ 34.5 M | USA |
 |
Senseonics Holdings
SENS
|
-68.3 M | $ 6.66 | 0.6 % | $ 278 M | USA |
 |
Sotera Health Company
SHC
|
248 M | $ 13.84 | -0.32 % | $ 3.93 B | USA |
 |
Celcuity
CELC
|
-113 M | $ 102.01 | -4.44 % | $ 4.02 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
1.38 B | $ 266.12 | 0.64 % | $ 22.1 B | USA |
 |
Soleno Therapeutics
SLNO
|
9.41 M | $ 31.34 | -1.2 % | $ 1.59 B | USA |
 |
Motus GI Holdings
MOTS
|
-11.9 M | - | -34.28 % | $ 263 K | Israel |
 |
ENDRA Life Sciences
NDRA
|
-10.8 M | $ 3.46 | -0.57 % | $ 1.86 M | USA |
 |
NeoGenomics
NEO
|
-116 M | $ 7.86 | -2.96 % | $ 1.01 B | USA |
 |
Neuronetics
STIM
|
-31.4 M | $ 1.46 | -9.06 % | $ 96.3 M | USA |
 |
Natera
NTRA
|
-541 M | $ 194.52 | -2.78 % | $ 19.1 B | USA |
 |
CareDx, Inc
CDNA
|
-30.8 M | $ 17.84 | 1.59 % | $ 951 M | USA |
 |
OPKO Health
OPK
|
-152 M | $ 1.13 | -1.74 % | $ 784 M | USA |
 |
Castle Biosciences
CSTL
|
8.67 M | $ 25.35 | -1.55 % | $ 704 M | USA |
 |
DarioHealth Corp.
DRIO
|
-36.7 M | $ 7.76 | 3.47 % | $ 30.9 M | Israel |
 |
DexCom
DXCM
|
912 M | $ 66.6 | 1.0 % | $ 26 B | USA |
 |
Exact Sciences Corporation
EXAS
|
-206 M | $ 104.91 | - | $ 19.8 B | USA |
 |
Twist Bioscience Corporation
TWST
|
-136 M | $ 47.49 | 6.72 % | $ 2.84 B | USA |